DOCSLIB.ORG

Molecular Characterization of Tea Catechin Treated Human Prostate Cancer Cell Lines Yewseok Suh

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Molecular Characterization of Tea Catechin Treated Human Prostate Cancer Cell Lines Yewseok Suh Florida State University Libraries Electronic Theses, Treatises and Dissertations The Graduate School 2006 Molecular Characterization of Tea Catechin Treated Human Prostate Cancer Cell Lines Yewseok Suh Follow this and additional works at the FSU Digital Library. For more information, please contact [email protected] THE FLORIDA STATE UNIVERSITY COLLEGE OF ARTS AND SCIENCES MOLECULAR CHARACTERIZATION OF TEA CATECHIN TREATED HUMAN PROSTATE CANCER CELL LINES By YEWSEOK SUH A Dissertation submitted to the Department of Chemistry and Biochemistry in partial fulfillment of the requirements for the degree of Doctor of Philosophy Degree Awarded: Summer Semester, 2006 The members of the Committee approve the dissertation of Yewseok Suh defended on May 12, 2006. Qing-Xiang Amy Sang Professor Directing Dissertation Thomas C.S. Keller III Outside Committee Member Joseph B. Schlenoff Committee Member Hong Li Committee Member Approved: Naresh Dalal, Chair, Department of Chemistry and Biochemistry Joseph Travis, Dean, College of Arts and Sciences The Office of Graduate Studies has verified and approved the above named committee members. ii This dissertation is dedicated to my parents for their endless love and encouragement, to my lovely wife Inok Park for her support, and to our charming daughter, Tae-won. iii ACKNOWLEDGEMENTS I would like to express my gratitude to my major professor for her support throughout the research. Also thanks to all my committee members, Dr. Thomas C. S. Keller III, Dr. Hong Li, and Dr. Joseph B. Schlenoff, for their support, advice, and guidance. Special thanks to our lab members especially, Ziad Sahab and Robert G. Newcomer and former lab member Douglas R. Hurst for their helpful and critical discussions. I would like to thank all my family members including my sister Sun-young, brother Seung-bum, and my uncle Dr. Jeong-hun Suh for their support and encouragement. It has been a pleasure and privilege to work in Dr. Sang’s lab for the past couple of years. iv TABLE OF CONTENTS List of Tables viii List of Figures ix List of Abbreviations xi Abstract xv 1. INTRODUCTION 1 Cancer 1 Cancer Statistics 1 Prostate Cancer 2 Apoptosis 3 Green Tea and EGCG 6 EGCG and Cancer 8 Figures and Tables 11 2. MATERIALS AND METHODS 17 Reagents and Cell Culture 17 Tea Polyphenol Treatment and Cell Lysis 17 Nuclear and Cytoplasmic Extraction of Cells 18 Determination of Protein Concentration by BCA Assay 19 SDS-PAGE and Western Blotting 19 Cell Proliferation Assay 20 Cell Death Detection Assay 21 DNA Fragmentation Assay 22 Morphological Analysis of Apoptotic Cell Nucleus 23 Cell Adhesion Assay 23 Anchorage-Independent Growth Assay 24 GeneChip Microarray Analysis 24 Total RNA Preparation 25 Reverse Transcription - Polymerase Chain Reaction 26 v Quantitative Measurements of proMMP1 and MMP3 by ELISA 27 Statistic Analysis of the Data 28 Figures and Tables 30 3. EFFECTS OF EGCG ON THE GROWTH AND APOTOSIS OF PROSTATE CANCER CELL LINES 34 Prostate Cancer and EGCG 34 R1881 Suppresses the Growth of ARCaP Cells but Facilitates LNCaP Cell Growth 36 EGCG Represses the Growth and Induces Detachment and Membrane Blebbing in Cultured LNCaP Cells but Not in ARCaP Cells 36 EGCG Induces Apoptosis in LNCaP Cells but Not in ARCaP Cells 37 EGCG Induces Chromatin Condensation and Nuclei Fragmentation in LNCaP Cells but Not in ARCaP Cells 38 EGCG Induces Caspase 3 Activation, PARP Cleavage and p53 Increase Only in LNCaP Cells Leading to Apoptosis 39 EGCG Triggers Activation of NF-κB in ARCaP Cells but Induces Inactivation in LNCaP Cells 40 EGCG Decreases the Ratio of Bax/Bcl-2 in ARCaP Cells but Increases the Ratio in LNCaP Cells 41 EGCG Does Not Change the Level of p21/CIP1/WAF1 and CDKs in ARCaP Cells but the Level is Affected in LNCaP Cells in Favor of Apoptosis 42 EGCG Affects the Activation of MAPKs towards Cell Survival in ARCaP Cells but Favors Cell Death in LNCaP Cells 44 EGCG Confers Stronger ECM Adhesion via Collagen in ARCaP Cells whereas the Adhesion to ECM Proteins is Significantly Weakened in LNCaP Cells 46 Tea Catechin EGCG Renders ARCaP Cells Capable of Facilitated Anchorage-Independent Growth 49 Figures 51 vi 4. SELECTIVE CHANGES IN GENE EXPRESSION IN EGCG TREATED PROSTATE CANCER CELLS 79 GeneChip Microarray Analysis 79 ADAMs and MMPs 81 Effects of Tea Catechins in Growth of LNCaP and ARCaP Cells 82 Effects of Tea Catechins in MMP1 and MMP3 Expression by RT-PCR 83 Effects of Tea Catechins in proMMP1 and MMP3 Expression by ELISA 84 The Effect of EGCG on the Expression of MMPs 86 The Role of MMPs and ECM in Programmed Cell Death 86 Figures and Tables 90 5. CONCLUSIONS AND FUTURE DIRECTIONS 103 EGCG and Prostate Cancer Chemoprevention 103 EGR1 in Apoptosis 104 Possible Roles of GADD45 and Topoisomerase 105 Current and Future Studies 106 Figures and Tables 108 APPENDIX 110 REFERENCES 157 BIOGRAPHICAL SKETCH 171 vii LIST OF TABLES 1. The composition of tea leaf 15 2. The information of primers used in PCR 32 3. The sequences of primers used in PCR 33 4. Changes of expression levels of adhesion-related proteins in LNCaP cells by GeneChip assay 90 5. Combinations of integrin subunits and their respective ligands 91 6. Changes of expression levels of ADAMs by GeneChip assay in LNCaP cells 92 7. Changes of expression levels of cell cycle-related proteins by GeneChip assay 108 8. The effect of R1881 on the growth of human prostate cancer cell lines 110 9. The effect of EGCG on the growth of LNCaP prostate cancer cell line 111 10. The effect of EGCG on the growth of ARCaP prostate cancer cell line 112 11. The ‘Enrichment Factor’ of ARCaP and LNCaP cells upon EGCG treatment measured by Cell Death Detection Assay PLUS 113 12. The ratio of Bax to Bcl-2 upon EGCG treatment 114 13. The effect of etoposide on the growth of ARCaP cells 115 14. Relative adherence of ARCaP cells to ECM proteins 116 15. Relative adherence of LNCaP cells to ECM proteins 117 16. The changes in relative adherence after EGCG treatment 118 17. The number of colonies formed in agar plate after EGCG treatment 119 18. GeneChip assay of ARCaP cells 120 19. GeneChip assay of LNCaP cells 130 20. The effect of tea catechins on the growth of LNCaP cells 151 21. The effect of tea catechins on the growth of ARCaP cells 152 22. The effect of tea catechins on the production of proMMP1 in LNCaP cells 153 23. The effect of tea catechins on the production of proMMP1 in ARCaP cells 154 24. The effect of tea catechins on the production of total MMP3 in LNCaP cells 155 25. The effect of tea catechins on the production of total MMP3 in ARCaP cells 156 viii LIST OF FIGURES 1. Estimated new cases and deaths by ten leading cancer types, by sex, US, 2006 11 2. Pictures of prostate and the model of prostate cancer progression 12 3. A picture of a cell undergoing apoptosis 13 4. The overview of apoptosis 14 5. Structures of basic flavonoid and major tea catechins 16 6. Schematic representation of Cell Death Detection ELISA PLUS assay 30 7. The schematic diagram of GeneChip assay 31 8. The effect of R1881 on the growth of ARCaP cells 51 9. The effect of green tea polyphenol EGCG on the growth of LNCaP human prostate cancer cells 52 10. The effect of green tea polyphenol EGCG on the growth of ARCaP human prostate cancer cells 53 11. Morphological changes upon EGCG addition in LNCaP cells 54 12. Morphological changes upon EGCG addition in ARCaP cells 55 13. The extent of apoptosis determined by Cell Death Detection Assay PLUS 56 14. The extent of apoptosis determined by DNA fragmentation assay 57 15. The extent of ARCaP cell apoptosis determined by Hoechst staining 58 16. The extent of LNCaP cell apoptosis determined by Hoechst staining 59 17. Immunoblot results with caspase 3 and PARP specific antibodies 60 18. Immunoblot results with p53 specific antibody 61 19. Immunoblot results with p65, phospho-p65, and Iκ-Bα specific antibodies 62 20. The role of Bcl-2 family members in mitochondrial outer membrane permeabilization during apoptosis 63 21. Immunoblot results with Bax, Bcl-2, and Bcl-XL specific antibodies 64 22. The changes of Bax/Bcl-2 ratio upon EGCG treatment 65 23. The role of p21/CIP1/WAF1 in cell cycle progression and apoptosis 66 24. Immunoblot results with p21, CDK2, CDK4, and CDK6 specific antibodies 67 25. The effects of etoposide on growth of ARCaP cells 68 26. The effects of etoposide on apoptosis of ARCaP cells 69 ix 27. Immunoblot results of etoposide treated ARCaP cell lysates with caspase 3, PARP, and p21 specific antibodies 70 28. Immunoblot results with Akt, p38, and JNK specific antibodies 71 29. Cell detachment assay of ARCaP cells 72 30. Cell detachment assay of LNCaP cells 73 31. Extracellular matrix adhesion assay of ARCaP cells 74 32. Extracellular matrix adhesion assay of LNCaP cells 75 33. The anchorage-independent growth assay of LNCaP cells 76 34. The anchorage-independent growth assay of ARCaP cells 77 35. The number of colonies formed in anchorage-independent growth assay 78 36. Changes of expression levels of MMPs by GeneChip assay in LNCaP cells 93 37. The effect of tea catechins on the growth of LNCaP cells 94 38. The effect of tea catechins on the growth of ARCaP cells 95 39. The effect of tea catechins on the expression of MMP1 and MMP3 mRNA in LNCaP cells 96 40. The effect of tea catechins on the expression of MMP1 and MMP3 mRNA in ARCaP cells 97 41.
Load more

Recommended publications
  • MOUSE INTERLEUKIN-28B/INTERFERON-LAMBDA 3, CARRIER FREE Product Number: 12821-1 Lot Number: 5559 Size: 25 Μg
    MOUSE INTERLEUKIN-28B/INTERFERON-LAMBDA 3, CARRIER FREE Product Number: 12821-1 Lot Number: 5559 Size: 25 µg Description: Mouse Interleukin-28B/Interferon-lambda 3, Carrier Free Source: A DNA sequence encoding the mature mouse IL-28B/IFN-λ3 (Asp 20 - Val 193) (Kotenko, S.V. et al., 2003, Nat. Immunol. 4(1):69 - 77) was expressed in E. coli. Form: Lyophilized Buffer: Phosphate-buffered saline (PBS) Reconstitution: It is recommended that sterile PBS be added to the vial to prepare a stock solution of no less than 100 μg/mL. Endotoxin: < 1 EU/µg Molecular Weight: The 175 amino acid residue methionyl form of recombinant mouse IL-28B has a predicted molecular mass of approximately 19.7 kDa. Purity: > 95% Synonyms: Mu IL-28B; Mu IFN-λ3 Accession #: NP_796370 Assays Used to Measure Bioactivity: Human HepG2 cells infected with encephalomyocarditis virus (Sheppard, P. et al., 2003, Nature Immunol. 4:63). The ED50 for this effect is typically 7.5 - 37.5 ng/mL. Shipping Conditions: Wet Ice Physical State of Product During Shipping: Lyophilized Special Conditions/Comments: After receipt, this product should be kept at -70˚C or below for retention of full activity. Upon reconstitution, this cytokine can be stored under sterile conditions at 2˚C to 8˚C for one month or at -20˚C to -70˚C in a manual defrost freezer for three months without detection loss of activity. Avoid repeated freeze-thaw cycles. For more information on protein handling, visit the PBL website at www.interferonsource.com . Product Information: Human IL-28A, IL-28B, and IL-29, also named interferon-λ2 (IFN-λ2), IFN-λ3, and IFN-λ1, respectively, are newly identified class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11- 13% aa sequence identity) and type I IFN family (15 - 19% aa sequence identity).1 – 3 The genes encoding these three cytokines are localized to chromosome 19 and each is composed of multiple exons.
    [Show full text]
  • 2018 Chen Lingyan 1448129
    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Genetics and Epigenetics in Systemic Lupus Erythematosus Chen, Lingyan Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 03. Oct. 2021 GENETICS AND EPIGENETICS IN SYSTEMIC LUPUS ERYTHEMATOSUS Lingyan CHEN Department of Medical & Molecular Genetics Faculty of Life Sciences & Medicine King’s College London This thesis is submitted for the degree of DoCtor of Philosophy (PhD) 1 To my parents 2 DeClaration The work described in this thesis was carried out within the Vyse Immunogenetics Group in the Department of Medical and Molecular Genetics at King’s College London under the supervision of Professor Timothy James Vyse and Dr David Lester Morris and between the years of October 2014 and March 2018.
    [Show full text]
  • Ncounter® Autoimmune Discovery Consortium Panel
    nCounter® Autoimmune Discovery Consortium Panel - Gene Details Official Symbol Accession Alias / Previous Symbol Official Full Name Other targets or Isoform Information AAMP NM_001087.3 angio associated migratory cell protein ABHD6 NM_020676.5 abhydrolase domain containing 6 ACKR2 NM_001296.3 CMKBR9,CCBP2;chemokine binding protein 2 atypical chemokine receptor 2 ACOXL NM_018308.1 acyl-Coenzyme A oxidase-like acyl-CoA oxidase like ACSL6 NM_001009185.1 FACL6;fatty-acid-Coenzyme A ligase, long-chain 6 acyl-CoA synthetase long chain family member 6 ADA NM_000022.2 adenosine deaminase ADAM30 NM_021794.2 a disintegrin and metalloproteinase domain 30 ADAM metallopeptidase domain 30 ADCY3 NM_004036.3 adenylate cyclase 3 ADCY7 NM_001114.4 adenylate cyclase 7 AFF3 NM_001025108.1 LAF4;lymphoid nuclear protein related to AF4,AF4/FMR2 family, member 3 AF4/FMR2 family member 3 AGAP2 NM_014770.3 CENTG1;centaurin, gamma 1 ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 AHI1 NM_001134830.1 Abelson helper integration site Abelson helper integration site 1 AHR NM_001621.3 aryl hydrocarbon receptor AHSA2;AHA1, activator of heat shock 90kDa protein ATPase homolog 2 AHSA2 NM_152392.1 (yeast),activator of HSP90 ATPase homolog 2 activator of HSP90 ATPase homolog 2, pseudogene APECED;autoimmune regulator (autoimmune polyendocrinopathy candidiasis AIRE NM_000383.2 ectodermal dystrophy) autoimmune regulator AMIGO3 NM_198722.2 adhesion molecule with Ig like domain 3 ANKRD55 NM_024669.2 ankyrin repeat domain 55 ANTXR2 NM_058172.5 anthrax toxin receptor
    [Show full text]
  • Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies
    viruses Review Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies Laura A. Novotny 1 , John Grayson Evans 1, Lishan Su 2, Haitao Guo 3 and Eric G. Meissner 1,4,* 1 Division of Infectious Diseases, Medical University of South Carolina, Charleston, SC 29525, USA; [email protected] (L.A.N.); [email protected] (J.G.E.) 2 Division of Virology, Pathogenesis, and Cancer, Institute of Human Virology, Departments of Pharmacology, Microbiology, and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA; [email protected] 3 Department of Microbiology and Molecular Genetics, Cancer Virology Program, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA; [email protected] 4 Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA * Correspondence: [email protected]; Tel.: +1-843-792-4541 Abstract: Hepatitis B virus (HBV) chronically infects over 250 million people worldwide and causes nearly 1 million deaths per year due to cirrhosis and liver cancer. Approved treatments for chronic infection include injectable type-I interferons and nucleos(t)ide reverse transcriptase inhibitors. A small minority of patients achieve seroclearance after treatment with type-I interferons, defined as sustained absence of detectable HBV DNA and surface antigen (HBsAg) antigenemia. However, type-I interferons cause significant side effects, are costly, must be administered for months, and most patients have viral rebound or non-response. Nucleos(t)ide reverse transcriptase inhibitors reduce HBV viral load and improve liver-related outcomes, but do not lower HBsAg levels or impart Citation: Novotny, L.A.; Evans, J.G.; seroclearance.
    [Show full text]
  • Cytokine-Targeted Therapeutics for KSHV-Associated Disease
    viruses Review Cytokine-Targeted Therapeutics for KSHV-Associated Disease Nedaa Alomari and Jennifer Totonchy * Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA 92618, USA; [email protected] * Correspondence: [email protected] Received: 1 September 2020; Accepted: 25 September 2020; Published: 28 September 2020 Abstract: Kaposi’s sarcoma-associated herpesvirus (KSHV) also known as human herpesvirus 8 (HHV-8), is linked to several human malignancies including Kaposi sarcoma (KS), primary effusion lymphoma (PEL), multicentric Castleman’s disease (MCD) and recently KSHV inflammatory cytokine syndrome (KICS). As with other diseases that have a significant inflammatory component, current therapy for KSHV-associated disease is associated with significant off-target effects. However, recent advances in our understanding of the pathogenesis of KSHV have produced new insight into the use of cytokines as potential therapeutic targets. Better understanding of the role of cytokines during KSHV infection and tumorigenesis may lead to new preventive or therapeutic strategies to limit KSHV spread and improve clinical outcomes. The cytokines that appear to be promising candidates as KSHV antiviral therapies include interleukins 6, 10, and 12 as well as interferons and tumor necrosis factor-family cytokines. This review explores our current understanding of the roles that cytokines play in promoting KSHV infection and tumorigenesis, and summarizes the current use of cytokines as therapeutic targets in KSHV-associated diseases. Keywords: KSHV; pathogenesis; cytokine signaling; cytokine therapeutics; cytokine targeted therapy; immunomodulatory therapeutics 1. Introduction In 1994, Kaposi’s sarcoma-associated herpesvirus (KSHV) was first identified in a Kaposi’s sarcoma (KS) lesion by Chang and Moore [1].
    [Show full text]
  • COVID-19: a Drug Repurposing and Biomarker Identification by Using Comprehensive Gene-Disease Associations Through Protein-Protein Interaction Network Analysis
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 30 March 2020 doi:10.20944/preprints202003.0440.v1 COVID-19: A drug repurposing and biomarker identification by using comprehensive gene-disease associations through protein-protein interaction network analysis Suresh Kumar* Department of Diagnostic and Allied Health Science, Faculty of Health & Life Sciences, Management & Science University, 40100 Shah Alam, Selangor, Malaysia *Corresponding author Suresh Kumar, PhD Department of Diagnostic and Allied Health Science, Faculty of Health & Life Sciences Management & Science University, 40100 Shah Alam, Selangor, Malaysia Email: [email protected] Abstract COVID-19 (2019-nCoV) is a pandemic disease with an estimated mortality rate of 3.4% (estimated by the WHO as of March 3, 2020). Until now there is no antiviral drug and vaccine for COVID-19. The current overwhelming situation by COVID-19 patients in hospitals is likely to increase in the next few months. About 15 percent of patients with serious disease in COVID-19 require immediate health services. Rather than waiting for new anti-viral drugs or vaccines that take a few months to years to develop and test, several researchers and public health agencies are attempting to repurpose medicines that are already approved for another similar disease and have proved to be fairly effective. This study aims to identify FDA approved drugs that can be used for drug repurposing and identify biomarkers among high- risk and asymptomatic groups. In this study gene-disease association related to COVID-19 reported mild, severe symptoms and clinical outcomes were determined. The high-risk group was studied related to SARS-CoV-2 viral entry and life cycle by using Disgenet and compared with curated COVID-19 gene data sets from the CTD database.
    [Show full text]
  • R J M E EVIEW Romanian Journal of R Morphology & Embryology
    Rom J Morphol Embryol 2020, 61(1):33–43 doi: 10.47162/RJME.61.1.04 R J M E EVIEW Romanian Journal of R Morphology & Embryology http://www.rjme.ro/ Host immune response in chronic hepatitis C infection: involvement of cytokines and inflammasomes MIHAIL VIRGIL BOLDEANU1,2), ISABELA SILOŞI1), ANDREEA LILI BĂRBULESCU3), RALUCA ELENA SANDU4), CRISTIANA GEORMĂNEANU5), VLAD PĂDUREANU6), MIRCEA VASILE POPESCU-DRIGĂ7), IOAN SABIN POENARIU7), CRISTIAN ADRIAN SILOŞI8), ANCA MARILENA UNGUREANU9), ANDA LORENA DIJMĂRESCU10), LIDIA BOLDEANU9) 1)Department of Immunology, University of Medicine and Pharmacy of Craiova, Romania 2)Medico Science SRL – Stem Cell Bank Unit, Craiova, Romania 3)Department of Pharmacology, University of Medicine and Pharmacy of Craiova, Romania 4)Department of Biochemistry, University of Medicine and Pharmacy of Craiova, Romania 5)Department of Emergency Medicine and First Aid, University of Medicine and Pharmacy of Craiova, Romania 6)Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, Romania 7)PhD Student, University of Medicine and Pharmacy of Craiova, Romania 8)Department of Surgery, University of Medicine and Pharmacy of Craiova, Romania 9)Department of Microbiology, University of Medicine and Pharmacy of Craiova, Romania 10)Department of Obstetrics and Gynecology, University of Medicine and Pharmacy of Craiova, Romania Abstract Chronic liver disease is a major health issue worldwide and chronic hepatitis C (CHC) is associated with an increased risk of cirrhosis and hepatocellular carcinoma (HCC). There is evidence that the hepatitis C virus (HCV) infection is correlated with immune senescence by way of immune activation and chronic inflammation, which lead to increased metabolic and cardiovascular risk, as well as progressive liver damage.
    [Show full text]
  • Control of the Physical and Antimicrobial Skin Barrier by an IL-31–IL-1 Signaling Network
    The Journal of Immunology Control of the Physical and Antimicrobial Skin Barrier by an IL-31–IL-1 Signaling Network Kai H. Ha¨nel,*,†,1,2 Carolina M. Pfaff,*,†,1 Christian Cornelissen,*,†,3 Philipp M. Amann,*,4 Yvonne Marquardt,* Katharina Czaja,* Arianna Kim,‡ Bernhard Luscher,€ †,5 and Jens M. Baron*,5 Atopic dermatitis, a chronic inflammatory skin disease with increasing prevalence, is closely associated with skin barrier defects. A cy- tokine related to disease severity and inhibition of keratinocyte differentiation is IL-31. To identify its molecular targets, IL-31–dependent gene expression was determined in three-dimensional organotypic skin models. IL-31–regulated genes are involved in the formation of an intact physical skin barrier. Many of these genes were poorly induced during differentiation as a consequence of IL-31 treatment, resulting in increased penetrability to allergens and irritants. Furthermore, studies employing cell-sorted skin equivalents in SCID/NOD mice demonstrated enhanced transepidermal water loss following s.c. administration of IL-31. We identified the IL-1 cytokine network as a downstream effector of IL-31 signaling. Anakinra, an IL-1R antagonist, blocked the IL-31 effects on skin differentiation. In addition to the effects on the physical barrier, IL-31 stimulated the expression of antimicrobial peptides, thereby inhibiting bacterial growth on the three-dimensional organotypic skin models. This was evident already at low doses of IL-31, insufficient to interfere with the physical barrier. Together, these findings demonstrate that IL-31 affects keratinocyte differentiation in multiple ways and that the IL-1 cytokine network is a major downstream effector of IL-31 signaling in deregulating the physical skin barrier.
    [Show full text]
  • SUPPLEMENTARY APPENDIX Exome Sequencing Reveals Heterogeneous Clonal Dynamics in Donor Cell Myeloid Neoplasms After Stem Cell Transplantation
    SUPPLEMENTARY APPENDIX Exome sequencing reveals heterogeneous clonal dynamics in donor cell myeloid neoplasms after stem cell transplantation Julia Suárez-González, 1,2 Juan Carlos Triviño, 3 Guiomar Bautista, 4 José Antonio García-Marco, 4 Ángela Figuera, 5 Antonio Balas, 6 José Luis Vicario, 6 Francisco José Ortuño, 7 Raúl Teruel, 7 José María Álamo, 8 Diego Carbonell, 2,9 Cristina Andrés-Zayas, 1,2 Nieves Dorado, 2,9 Gabriela Rodríguez-Macías, 9 Mi Kwon, 2,9 José Luis Díez-Martín, 2,9,10 Carolina Martínez-Laperche 2,9* and Ismael Buño 1,2,9,11* on behalf of the Spanish Group for Hematopoietic Transplantation (GETH) 1Genomics Unit, Gregorio Marañón General University Hospital, Gregorio Marañón Health Research Institute (IiSGM), Madrid; 2Gregorio Marañón Health Research Institute (IiSGM), Madrid; 3Sistemas Genómicos, Valencia; 4Department of Hematology, Puerta de Hierro General University Hospital, Madrid; 5Department of Hematology, La Princesa University Hospital, Madrid; 6Department of Histocompatibility, Madrid Blood Centre, Madrid; 7Department of Hematology and Medical Oncology Unit, IMIB-Arrixaca, Morales Meseguer General University Hospital, Murcia; 8Centro Inmunológico de Alicante - CIALAB, Alicante; 9Department of Hematology, Gregorio Marañón General University Hospital, Madrid; 10 Department of Medicine, School of Medicine, Com - plutense University of Madrid, Madrid and 11 Department of Cell Biology, School of Medicine, Complutense University of Madrid, Madrid, Spain *CM-L and IB contributed equally as co-senior authors. Correspondence:
    [Show full text]
  • Ncounter® Host Response Panel - Gene and Probe Details
    nCounter® Host Response Panel - Gene and Probe Details Gene Accession Synonyms Full Name Other targets or Isoform Information ACE NM 000789.2 DCP1;angiotensin I converting enzyme (peptidyl-dipeptidase A) 1;ACE1,CD143;peptidyl-dipeptidase A angiotensin I converting enzyme ACKR2 NM 001296.5 CMKBR9,CCBP2;chemokine binding protein 2;CCR10,D6,CCR9 atypical chemokine receptor 2 ACKR3 NM 020311.1 CMKOR1,CXCR7;chemokine orphan receptor 1,chemokine (C-X-C motif) receptor 7;RDC1,GPR159 atypical chemokine receptor 3 ACKR4 NM 016557.2 CCRL1;chemokine (C-C motif) receptor-like 1;CCR11,CCBP2,VSHK1,CCX-CKR,PPR1 atypical chemokine receptor 4 ACOX1 NM 001185039.1 acyl-Coenzyme A oxidase 1, palmitoyl,acyl-CoA oxidase 1, palmitoyl;PALMCOX;palmitoyl-CoA oxidase acyl-CoA oxidase 1 FACL2;fatty-acid-Coenzyme A ligase, long-chain 2;LACS2,LACS,ACS1,LACS1,FACL1;lignoceroyl-CoA synthase,long-chain fatty-acid- ACSL1 NM_001995.4 coenzyme A ligase 1 acyl-CoA synthetase long chain family member 1 ACSL3 NM 203372.1 FACL3;fatty-acid-Coenzyme A ligase, long-chain 3;ACS3,PRO2194 acyl-CoA synthetase long chain family member 3 FACL4,MRX63,MRX68;fatty-acid-Coenzyme A ligase, long-chain 4,mental retardation, X-linked 63,mental retardation, X-linked ACSL4 NM_004458.2 68;ACS4,LACS4;lignoceroyl-CoA synthase, long-chain fatty-acid-Coenzyme A ligase 4 acyl-CoA synthetase long chain family member 4 ACVR1 NM 001105.2 ACVRLK2;activin A receptor, type I;SKR1,ALK2,ACVR1A activin A receptor type 1 ADAR NM 001025107.1 IFI4,G1P1;interferon-induced protein 4;ADAR1 adenosine deaminase RNA
    [Show full text]
  • (MDR/TAP), Member 1 ABL1 NM 00
    Official Symbol Accession Official Full Name ABCB1 NM_000927.3 ATP-binding cassette, sub-family B (MDR/TAP), member 1 ABL1 NM_005157.3 c-abl oncogene 1, non-receptor tyrosine kinase ADA NM_000022.2 adenosine deaminase AHR NM_001621.3 aryl hydrocarbon receptor AICDA NM_020661.1 activation-induced cytidine deaminase AIRE NM_000383.2 autoimmune regulator APP NM_000484.3 amyloid beta (A4) precursor protein ARG1 NM_000045.2 arginase, liver ARG2 NM_001172.3 arginase, type II ARHGDIB NM_001175.4 Rho GDP dissociation inhibitor (GDI) beta ATG10 NM_001131028.1 ATG10 autophagy related 10 homolog (S. cerevisiae) ATG12 NM_004707.2 ATG12 autophagy related 12 homolog (S. cerevisiae) ATG16L1 NM_198890.2 ATG16 autophagy related 16-like 1 (S. cerevisiae) ATG5 NM_004849.2 ATG5 autophagy related 5 homolog (S. cerevisiae) ATG7 NM_001136031.2 ATG7 autophagy related 7 homolog (S. cerevisiae) ATM NM_000051.3 ataxia telangiectasia mutated B2M NM_004048.2 beta-2-microglobulin B3GAT1 NM_018644.3 beta-1,3-glucuronyltransferase 1 (glucuronosyltransferase P) BATF NM_006399.3 basic leucine zipper transcription factor, ATF-like BATF3 NM_018664.2 basic leucine zipper transcription factor, ATF-like 3 BAX NM_138761.3 BCL2-associated X protein BCAP31 NM_005745.7 B-cell receptor-associated protein 31 BCL10 NM_003921.2 B-cell CLL/lymphoma 10 BCL2 NM_000657.2 B-cell CLL/lymphoma 2 BCL2L11 NM_138621.4 BCL2-like 11 (apoptosis facilitator) BCL3 NM_005178.2 B-cell CLL/lymphoma 3 BCL6 NM_001706.2 B-cell CLL/lymphoma 6 BID NM_001196.2 BH3 interacting domain death agonist BLNK NM_013314.2
    [Show full text]
  • Transcriptomic Analysis Reveals Priming of the Host Antiviral
    International Journal of Molecular Sciences Article Transcriptomic Analysis Reveals Priming of The Host Antiviral Interferon Signaling Pathway by Bronchobini® Resulting in Balanced Immune Response to Rhinovirus Infection in Mouse Lung Tissue Slices Stella Marie Reamon-Buettner 1 , Monika Niehof 1 , Natalie Hirth 2, Olga Danov 1 , Helena Obernolte 1, Armin Braun 1, Jürgen Warnecke 2, Katherina Sewald 1 and Sabine Wronski 1,* 1 Department of Preclinical Pharmacology and In Vitro Toxicology, Fraunhofer Institute for Toxicology and Experimental Medicine, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Member of Fraunhofer international Consortium for Anti-Infective Research (iCAIR), 30625 Hannover, Germany; [email protected] (S.M.R.-B.); [email protected] (M.N.); [email protected] (O.D.); [email protected] (H.O.); [email protected] (A.B.); [email protected] (K.S.) 2 Heel GmbH, 76532 Baden-Baden, Germany; [email protected] (N.H.); [email protected] (J.W.) * Correspondence: [email protected]; Tel.: +49-511-5350-444 Received: 26 March 2019; Accepted: 30 April 2019; Published: 7 May 2019 Abstract: Rhinovirus (RV) is the predominant virus causing respiratory tract infections. Bronchobini® is a low dose multi component, multi target preparation used to treat inflammatory respiratory diseases such as the common cold, described to ease severity of symptoms such as cough and viscous mucus production. The aim of the study was to assess the efficacy of Bronchobini® in RV infection and to elucidate its mode of action.
    [Show full text]